title: [Etolip and Lipanthyl in the treatment of hyperlipoproteinemia].
abstract: Within the framework of clinical tests of Etolip (ethophylline clofibrate cps. 125 mg, Pharmaceutical Research Institute Modra) this preparation was administered to 28 patients with different types of hyperlipoproteinaemia in a specialized clinic for disorders of the lipid metabolism. The period of administration was four weeks, the dose 2 cps. twice a day. The effect of this new hypolipidaemic drug was compared with that of Lipathyl. Treatment with Etolip did not affect significantly the cholesterol and triacylglycerol levels, and the concentrations of apolipoprotein B and LDL-cholesterol did not change significantly. All these parameters were affected favourably and significantly by Lipanthyl. Etolip treatment had the favourable effect of elevating the HDL-cholesterol and apolipoprotein A-I level. Etolip was well tolerated by patients and no undesirable side-effects developed. The effects of Etolip as a hypolipidaemic agent are relatively small and are markedly lower than the effect of other registered hypolipidaemics available in the CSSR.
authors.affiliation: III. interní katedra fakulty vseobecného lékarství UK, Praha.
authors.forename: R
authors.initials: R
authors.lastname: Ceska
authors.forename: J
authors.initials: J
authors.lastname: Sobra
authors.forename: R
authors.initials: R
authors.lastname: Procházková
authors.forename: M
authors.initials: M
authors.lastname: Kvasilová
mesh_terms: D002994:Clofibrate / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D011345:Fenofibrate / Q000627:therapeutic use*; D006801:Humans; D006951:Hyperlipoproteinemias / Q000097:blood / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011422:Propionates / Q000627:therapeutic use*
chemical_list: D000960:Hypolipidemic Agents; D011422:Propionates; C028764:etofylline clofibrate; D002994:Clofibrate; D011345:Fenofibrate
vernacular_title: Etolip a Lipanthyl v lécbĕ hyperlipoproteinémií.